DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the business’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $84.41, for a total transaction of $300,499.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
John Lister also recently made the following trade(s):
- On Friday, September 9th, John Lister sold 3,560 shares of DexCom stock. The shares were sold at an average price of $93.65, for a total transaction of $333,394.00.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 81.68 on Monday. DexCom Inc. has a one year low of $47.92 and a one year high of $96.38. The company’s market capitalization is $6.85 billion. The stock has a 50 day moving average of $89.65 and a 200-day moving average of $78.55.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The firm earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The company’s revenue was up 47.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.05) earnings per share. On average, equities analysts expect that DexCom Inc. will post ($0.57) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in DXCM. BNP Paribas Arbitrage SA raised its stake in DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares in the last quarter. Bellwether Investment Group LLC bought a new stake in shares of DexCom during the second quarter worth about $119,000. Bank of Montreal Can bought a new stake in shares of DexCom during the second quarter worth about $134,000. Capstone Asset Management Co. bought a new stake in shares of DexCom during the third quarter worth about $205,000. Finally, Private Bank & Trust Co. bought a new stake in shares of DexCom during the third quarter worth about $220,000. 99.28% of the stock is owned by institutional investors.
DXCM has been the subject of several recent analyst reports. Zacks Investment Research cut shares of DexCom from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 4th. Desjardins raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, September 16th. Benchmark Co. dropped their target price on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Jefferies Group reiterated a “positive” rating and set a $98.00 target price on shares of DexCom in a research report on Friday, July 22nd. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating and set a $92.00 target price for the company. in a research report on Wednesday, September 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $95.40.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.